- Home
- TLPH vs NLSP Comparison
TLPH vs NLSP Comparison
Compare TLPH & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- NLSP
- Stock Information
- Founded
- TLPH 2005
- NLSP 2015
- Country
- TLPH United States
- NLSP Switzerland
- Employees
- TLPH N/A
- NLSP N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- TLPH Health Care
- NLSP Health Care
- Exchange
- TLPH Nasdaq
- NLSP Nasdaq
- Market Cap
- TLPH 11.1M
- NLSP 12.4M
- IPO Year
- TLPH 2011
- NLSP 2021
- Fundamental
- Price
- TLPH $0.79
- NLSP $1.96
- Analyst Decision
- TLPH Strong Buy
- NLSP
- Analyst Count
- TLPH 1
- NLSP 0
- Target Price
- TLPH $6.00
- NLSP N/A
- AVG Volume (30 Days)
- TLPH 3.4M
- NLSP 217.3K
- Earning Date
- TLPH 08-14-2025
- NLSP 10-17-2025
- Dividend Yield
- TLPH N/A
- NLSP N/A
- EPS Growth
- TLPH N/A
- NLSP N/A
- EPS
- TLPH N/A
- NLSP N/A
- Revenue
- TLPH $27,000.00
- NLSP N/A
- Revenue This Year
- TLPH N/A
- NLSP N/A
- Revenue Next Year
- TLPH $14,533.26
- NLSP N/A
- P/E Ratio
- TLPH N/A
- NLSP N/A
- Revenue Growth
- TLPH N/A
- NLSP N/A
- 52 Week Low
- TLPH $0.38
- NLSP $1.30
- 52 Week High
- TLPH $1.19
- NLSP $6.97
- Technical
- Relative Strength Index (RSI)
- TLPH 84.46
- NLSP 39.28
- Support Level
- TLPH $0.40
- NLSP $1.88
- Resistance Level
- TLPH $0.57
- NLSP $2.02
- Average True Range (ATR)
- TLPH 0.10
- NLSP 0.16
- MACD
- TLPH 0.02
- NLSP -0.06
- Stochastic Oscillator
- TLPH 56.72
- NLSP 8.67
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.